Boundless Bio Cuts Staff as Lead Drug Faces Setbacks

Highlights

• Boundless Bio lays off one-third of its staff amid clinical trial setbacks.
• Phase 1/2 data reveals hematological toxicity limits continuous dosing of lead candidate BBI-355 as monotherapy.
• Combination therapies with erlotinib and futibatinib showed poor tolerability, halting current trial arms.
• Company shifts focus to combining BBI-355 with BBI-825, citing promising preclinical synergy and reduced toxicity.
• BBI-940 selected for further development in kinesin degrader program, with clinical trials planned in 2026.
• Layoffs extend Boundless’ cash runway into the first half of 2028, supporting upcoming clinical milestones.

Trial Results Force Strategic Shift

San Diego-based biotechnology company Boundless Bio has announced significant operational changes after its lead drug candidate encountered challenges in clinical trials. The company's phase 1/2 study revealed critical limitations of BBI-355, its CHK1 inhibitor, prompting Boundless to lay off approximately one-third of its workforce and adjust its development strategy.

Following a $100 million IPO last year aimed at advancing phase 1/2 trials of two molecules, BBI-355 and BBI-825, Boundless faced a setback when it halted development of its RNR inhibitor BBI-825 in December due to insufficient dose-proportional exposure. Subsequently, the company concentrated efforts on BBI-355, seeking preliminary clinical proof-of-concept data on safety and antitumor activity.

Lead Candidate's Limitations Impact Development Plans

The preliminary data from the phase 1/2 trial revealed that BBI-355 could not be advanced as a single agent with continuous dosing. According to the report, "the phase 1/2 study in patients with oncogene-amplified solid tumors saw hematological toxicity at or near doses associated with clinical activity," resulting in a narrow therapeutic window that undermined monotherapy ambitions.

Boundless also evaluated BBI-355 in combination with the EGFR inhibitor erlotinib and the FGFR inhibitor futibatinib (marketed by Taiho Oncology as Lytgobi). However, these combination regimens were poorly tolerated at doses necessary to achieve sustained antitumor efficacy. These findings compelled Boundless to discontinue further development of the current arms in the ongoing trial.

New Direction: Combination Therapy and Kinesin Degrader Program

With monotherapy development halted for both BBI-355 and BBI-825, Boundless is pivoting to a novel approach testing the two candidates in combination. The company highlighted a "strong mechanistic rationale for the cocktail," emphasizing that the combination may avoid overlapping toxicities and eliminate the need for continuous dosing.

Preclinical studies demonstrated "synergistic cytotoxicity in cancer cell lines and tumor regression in mouse xenograft models using weekly dosing at exposures not associated with hematological toxicity." Boundless plans to initiate clinical development of this combination later this year.

Additionally, Boundless announced the selection of BBI-940 as the lead candidate from its kinesin degrader program, with plans to file for human clinical trials in the first half of 2026.

Workforce Reduction Extends Financial Runway

To support its revised clinical strategy and extend its financial resources, Boundless has implemented layoffs affecting about 33% of its staff. The company reported, "Boundless had 64 employees as of March 21," down from 72 one year prior, with previous layoffs occurring in August 2024 due to slow enrollment in the BBI-355 trial.

These recent cuts have extended the company's cash runway from a previously announced horizon into 2027 to now well into the first half of 2028, ensuring continued funding for upcoming proof-of-concept clinical readouts for both the combination therapy and BBI-940.